KR950700402A - 세포용해성 t 세포전구체를 결정하는 방법(method for determining cytolytic t cell precursors) - Google Patents

세포용해성 t 세포전구체를 결정하는 방법(method for determining cytolytic t cell precursors)

Info

Publication number
KR950700402A
KR950700402A KR1019940702508A KR19940702508A KR950700402A KR 950700402 A KR950700402 A KR 950700402A KR 1019940702508 A KR1019940702508 A KR 1019940702508A KR 19940702508 A KR19940702508 A KR 19940702508A KR 950700402 A KR950700402 A KR 950700402A
Authority
KR
South Korea
Prior art keywords
cells
tumor
antigen
cytolytic
subject
Prior art date
Application number
KR1019940702508A
Other languages
English (en)
Korean (ko)
Inventor
지. 큐리 피에르
분 씨에리
Original Assignee
로이트 제이. 오울드. 에드워드 에이. 맥더모르쎄
루드윅 인스티튜트 포 캔서 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로이트 제이. 오울드. 에드워드 에이. 맥더모르쎄, 루드윅 인스티튜트 포 캔서 리서치 filed Critical 로이트 제이. 오울드. 에드워드 에이. 맥더모르쎄
Publication of KR950700402A publication Critical patent/KR950700402A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
KR1019940702508A 1992-01-21 1993-01-07 세포용해성 t 세포전구체를 결정하는 방법(method for determining cytolytic t cell precursors) KR950700402A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82393392A 1992-01-21 1992-01-21
US07/823.933 1992-01-21
PCT/US1993/000083 WO1993014189A1 (fr) 1992-01-21 1993-01-07 Procede de determination de precurseurs de lymphocytes t cytolytiques

Publications (1)

Publication Number Publication Date
KR950700402A true KR950700402A (ko) 1995-01-16

Family

ID=25240169

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702508A KR950700402A (ko) 1992-01-21 1993-01-07 세포용해성 t 세포전구체를 결정하는 방법(method for determining cytolytic t cell precursors)

Country Status (8)

Country Link
EP (1) EP0624189A4 (fr)
JP (1) JPH07503134A (fr)
KR (1) KR950700402A (fr)
AU (1) AU3435293A (fr)
CA (1) CA2128424A1 (fr)
FI (1) FI943422A (fr)
NO (1) NO942660L (fr)
WO (1) WO1993014189A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664560B2 (en) * 1991-05-23 1995-11-23 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6352826B1 (en) 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
JPH10505481A (ja) 1994-04-22 1998-06-02 アメリカ合衆国 メラノーマ抗原
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
WO1997026328A1 (fr) * 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
EP0943095A2 (fr) * 1996-11-22 1999-09-22 Shiloov Medical Technologies, Ltd. Procede et trousse de dosage du sang entier et du facteur mitogene servant a effectuer la detection precoce du cancer chez un sujet

Also Published As

Publication number Publication date
AU3435293A (en) 1993-08-03
FI943422A0 (fi) 1994-07-19
JPH07503134A (ja) 1995-04-06
NO942660D0 (no) 1994-07-15
FI943422A (fi) 1994-07-19
EP0624189A1 (fr) 1994-11-17
EP0624189A4 (fr) 1995-05-17
WO1993014189A1 (fr) 1993-07-22
NO942660L (no) 1994-09-16
CA2128424A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
KR950700402A (ko) 세포용해성 t 세포전구체를 결정하는 방법(method for determining cytolytic t cell precursors)
DE3476421D1 (en) Microbiological testing apparatus
ES530691A0 (es) Un procedimiento de ensayo para la deteccion de la presencia de un derivado de fibrina reticulado en un fluido corporal de un animal.
ATE136909T1 (de) Igg3-antikörper mit verkürzter hinge-region und einem komplementaktivierungstest
Slein et al. Partial purification and properties of two phospholipases of Bacillus cereus
NO932320L (no) Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne
Lan et al. Controversies and considerations in the diagnosis of primary cutaneous CD4+ small/medium T-cell lymphoma
Weber et al. Caribbean Reef Corals Montastrea annularis and Montastrea cavernosa--Long-Term Growth Data as Determined by Skeletal X-radiography: Reef Biota
DE3789781D1 (de) Antigene, Antikörper und Verfahren zur Identifizierung humaner metastatischer Tumoren und Zellinien zur Herstellung dieser Antikörper.
Schnell Ice nuclei produced by laboratory cultured marine phytoplankton
DE69123723D1 (de) Diagnostisches verfahren und reagenz für hiv
DE59300909D1 (de) Verfahren zur immunologischen erkennung maligner tumore und kit zur durchführung dieses verfahrens.
Constans et al. Relationship between Hp1S and Hp2 gene frequencies among human populations
Watson Jr et al. Detection of tumor-specific antigens in an equine sarcoid cell line
ATA261687A (de) Laktoferrin enthaltendes inkubationsmedium für festphasen-immunometrische verfahren und seine verwendung
DE69534876D1 (de) Nematizides mittel und verfahren zur biologischen bekämpfung von nematoden
McKenna et al. Studies on the antigens of human tumors: II. Demonstration of a soluble specific antigen (G) in cell lines derived from malignant human tissue
Zykov et al. Non-tuberculosis mycobacteria in Africa: 3. Formamidase activity—its evaluation and practical application
Çavdar et al. Effect of Human Serum Thymic Factor on Immature T Lymphocytes in Acute Leukemia and other Hematologic Malignancies
Heatherman Interrelationships between biochemical properties and susceptibility to antibiotics and sulfathiazole of strains of viridans streptococci and enterococci
Star VARIATION AND COVARIATION IN THE PLANKTON OF THE EUPHOTIC ZONE IN THE NORTH PACIFIC OCEAN.
Sabater et al. A simple identification system for rapidly growing mycobacteria (a note)
Bruce Mutants of the biological clock in Chlamydomonas reinhardi.
NOLL Carbon monoxide and disequilibrium dynamics in Saturn and Jupiter(Ph. D. Thesis)
Kick Refraction seismic investigation at Zemu Glacier, Sikkim: comments on the paper of RN Bose, NP Dutta and SM Lahiri

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid